Randomized Comparison of Piperacillin/Tazobactam Versus Imipenem/Cilastatin in the Treatment of Patients with Intra-abdominal Infection

Erasmo, Alex A.; Crisostomo, Armando C.; Yan, Lü-Nan; Hong, Yun-Sik; Lee, Kuhn-Uk; Lo, Chung‐Mau

doi:10.1016/s1015-9584(09)60039-7

Cited by 23 publications

(33 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…From this study, it was found that the isolates were mostly sensitive (89% -84%) to the drugs like amikacin, imipenem, cefoperazone-sulbactam followed by meropenem, ciprofloxacin, ceftazidime, ticarcillin-clavulanic acid (all in the range of 78% -74%) and lastly against ceftriaxonetazobactam and gentamicin (68%-63%). These pathogens showed high resistance to tetracycline, piperacillin, cefotaxime, azithromycin, oxacillin, mecilinam and gatifloxacin (approx 68% -47%) which were also reported by workers like Erasmo et al (2004), Sivanmaliappan and Sevanan (2011) and Hill et al (2005) showing resistance of this pathogen against piperacillin, ticarcillin and tetracycline, ceftazidime, co-trimoxazole and cefoperazone in various degrees. Javiya et al (2008) reported that drugs like ticarcillin, piperacillin or 3 rd generation cephalosporins viz.…”

Section: In-vitro Antibiotic Sensitivity Test (Ast) Ofsupporting

confidence: 67%

Mice pathology study of toxA and exoS genes bearing Pseudomonas aeruginosa isolated from bovine Sub-clinical mastitis in West Begal with their Antibiogram

Banerjee

Batabyal

Joardar

et al. 2017

IJAR

View full text Add to dashboard Cite

Sub-clinical Mastitis is one of the major problems in India which is among the largest milk producing countries in the world, hampering national economy. Among 422 bovine milk samples screened from different cattle farms of West Bengal with history of infection and drop in milk yield by on-spot bromothymol blue (BTB) test, 371 samples were considered for collection and secondary screening by somatic cell count study. The collected milk samples showed significantly high average SCC value of 3.26-4.88 lakh cells/ml of milk which was indicative of infection. Samples (23, 6.53%) were found to be positive for Pseudomonas sp. showing distinct bluish-green pigmentation on cetrimide agar, typical results on morphological and in biochemical characterization. Presence of 19 (5.39%) Pseudomonas aeruginosa isolates were confirmed by fluorescent technique for detection of characteristic blue-green fluorescence by the pigment pyoverdin. PCR of these positive isolates revealed that 11 isolates were positive for toxA and 6 isolates for exoS genes with 2 isolates possessing both the genes. In Mice pathogenicity test, highest fatality (100%) was shown by the isolates with both the genes followed by isolates with toxA (66.67%) and exoS (41.67%) respectively with successful re-isolation of P. aeruginosa from the dead mice. Post-mortem examination of the dead mice showed marked haemorrhages on liver, blackish discoloration of intestines and haemorrhages on lungs. Antibiogram revealed that the isolates were highly sensitive to drugs like amikacin (89.47%), imipenem (84.21%), meropenem (78.95%) and cefoperazone-sulbactam (84.21%) but resistant to tetracycline (68.42%), piperacillin (63.16%), oxacillin (52.63%), mecilinam (47.37%) and others.

show abstract

Section: In-vitro Antibiotic Sensitivity Test (Ast) Ofsupporting

confidence: 67%

Mice pathology study of toxA and exoS genes bearing Pseudomonas aeruginosa isolated from bovine Sub-clinical mastitis in West Begal with their Antibiogram

Banerjee

Batabyal

Joardar

et al. 2017

IJAR

View full text Add to dashboard Cite

show abstract

“…Contrary to this resistance rate in isolates was higher in our study (42%). In a previous study equivalent safety and efficacy of intravenous Piperacillin/tazobactam with intravenous imipenem/cilastatin was reported for intra-abdominal infections caused by Pseudomonas aeruginosa but presently resistance was different for both antibiotics which might be due to extensive usage of this combination in our hospitals as life saving antibiotics (Erasmo et al 2004). …”

Section: Discussionmentioning

confidence: 56%

Antimicrobial susceptibility pattern of clinical isolates of Pseudomonas aeruginosa isolated from patients of lower respiratory tract infections

et al. 2012

View full text Add to dashboard Cite

The present study was conducted to determine the antibiotic susceptibility pattern of Pseudomonas aeruginosa from sputum samples of lower respiratory tract infection patients admitted to different hospitals of Karachi. Most of the hospitals are hampered with high frequency of nosocomial infections generally caused by multiresistant nosocomial pathogen. Among Gram-negative pathogens Pseudomonas aeruginosa considered as most challenging pathogen. The objective of the study was to determine frequency of Pseudomonas aeruginosa from sputum samples and to find out susceptibility pattern against four antibiotics widely used for treatment. The sputum samples from 498 patients were collected consecutively between January 2010 and March 2011 and were cultured and identified. According to CLSI (Clinical Laboratory Standards Institute) guidelines antimicrobial susceptibility testing was performed by disc diffusion method. Pseudomonas aeruginosa were isolated from 24% (120/498) of the lower respiratory tract patient. A higher resistance to Pseudomonas aeruginosa isolate was observed with piperacillin/tazobactam and cefipime i.e. 42% and 40% respectively. Imipenem was found to be most effective antibiotic against Pseudomonas aeruginosa (76% sensitivity) but amikacin resistance was continuously increasing. In conclusion the frequency of Pseudomonas aeruginosa was also higher among lower respiratory tract infection patients with alarmingly high rate of resistance among widely used antibiotics. These findings focused on careful consideration for monitoring and optimization of antimicrobial use in order to reduce occurrence and spread of antimicrobial resistant pathogen.

show abstract

“…Clinical outcome data of piperacillin-tazobactam versus comparators have been extensively reviewed elsewhere [72] and therefore will not be discussed in detail. Suffice to say, piperacillin-tazobactam has been shown to be as effective and safe as imipenem-cilastatin or doripenem for nosocomial pneumonia [73,74], as imipenem-cilastatin or ertapenem for complicated intra-abdominal infections [75][76][77][78], as meropenem, cefepime, ceftazidime, or piperacillin-tazobactam plus amikacin for febrile neutropenia [79][80][81][82], as ertapenem or imipenemcilastatin for diabetic foot infection [83,84], as ertapenem for complicated skin and soft tissue infections [85,86], and as ertapenem for acute pelvic infections [87]. Therefore, piperacillin-tazobactam has been recommended in various clinical guidelines for treatment of a wide range of infections [2-9].…”

Section: Clinical Outcome Datamentioning

confidence: 99%

Pharmacokinetic evaluation of piperacillin-tazobactam

Hayashi

Roberts

Paterson

et al. 2010

Expert Opinion on Drug Metabolism & Toxicology

View full text Add to dashboard Cite

show abstract

Randomized Comparison of Piperacillin/Tazobactam Versus Imipenem/Cilastatin in the Treatment of Patients with Intra-abdominal Infection

Abstract: These results suggest that the safety and efficacy of piperacillin/tazobactam administered every 8 hours are equivalent to those of imipenem/cilastatin administered every 6 hours for the treatment of intra-abdominal infections.

Cited by 23 publications

References 11 publications

Mice pathology study of toxA and exoS genes bearing Pseudomonas aeruginosa isolated from bovine Sub-clinical mastitis in West Begal with their Antibiogram

Mice pathology study of toxA and exoS genes bearing Pseudomonas aeruginosa isolated from bovine Sub-clinical mastitis in West Begal with their Antibiogram

Antimicrobial susceptibility pattern of clinical isolates of Pseudomonas aeruginosa isolated from patients of lower respiratory tract infections

Pharmacokinetic evaluation of piperacillin-tazobactam

Contact Info

Product

Resources

About